
Opinion|Videos|June 2, 2025
Considerations for Ruxolitinib Therapy in Steroid-Refractory cGVHD
Panelists discuss how clinicians typically taper steroids slowly after starting second-line agents for chronic graft-vs-host disease (cGVHD).
Advertisement
Episodes in this series

Steroid Tapering with Second-Line Therapy
This detailed segment covers approaches to steroid tapering when initiating second-line therapy. The panelists agree on:
- Waiting 3-4 weeks after starting a new agent (like ruxolitinib) before beginning steroid taper
- Prioritizing steroid discontinuation before tapering other agents
- Tapering steroids by approximately 10mg every 4 weeks, slowing the taper at lower doses
- Very gradual tapering of ruxolitinib once steroids are discontinued, sometimes using alternate-day dosing
Dr Lee notes that at Fred Hutchinson Cancer Center, they taper ruxolitinib more slowly than the prescribing information recommends, sometimes tapering to 5 mg several days per week before complete discontinuation.
Advertisement
Related to this article

Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.

Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.

The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.

Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.

Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.

Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.

The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
4
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer
5
